Unfit for Purpose...

Incognito asks how 'fit for purpose' are your system suitability tests?

Incognito asks how ‘fit for purpose’ are your system suitability tests?

Click here for the full article in The Column

Articles in this issue

over 13 years ago

Article

Spectrum and PerkinElmer announce distribution agreement

over 13 years ago

Article

Waters takes gold

Newsletter

Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.

Subscribe Now!

Related Content

Best of the Week: RNA-Based Therapeutics, GLP-1 Treatment

ByWill Wetzel

December 5th 2025

Study Shows Py-GC-MS Outperforms Traditional GC-MS for THC Edible Forensics

ByJohn Chasse

December 5th 2025

GLP-1 Therapies from Early Research to Clinical Evaluation

ByJudith Hey-Hadavi,Nicole Snow

December 5th 2025

Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling

ByJohn Chasse

December 4th 2025

Navigating Adverse Reactions in GLP-1 Treatment

ByJudith Hey-Hadavi,Nicole Snow

December 4th 2025

Unfit for Purpose...

Articles in this issue

Newsletter

Related Content

Best of the Week: RNA-Based Therapeutics, GLP-1 Treatment

Study Shows Py-GC-MS Outperforms Traditional GC-MS for THC Edible Forensics

GLP-1 Therapies from Early Research to Clinical Evaluation

Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling

Navigating Adverse Reactions in GLP-1 Treatment

Trending on LCGC International

Toward Safer Diabetes Devices: GC–MS Detection of Allergens in Sensors, Pumps, and Infusion Sets

Decoding Sweet Potato Drought Resilience: Metabolomic Evidence from UPLC-MS Profiling

Sustainability, Leadership, and Strategic Evolution at Knauer

Navigating Adverse Reactions in GLP-1 Treatment

Advancing RNA-Based Therapeutics: IQ Consortium Experts on Optimizing Chromatographic Bioanalysis